Journal article icon

Journal article

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial

Abstract:

Background: Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV.

Methods: In this single-arm open-label vaccination substudy within the protocol of the larger phase 2/3 trial COV002, ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1016/S2352-3018(21)00103-X

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Biomedical Services
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Biomedical Services
Role:
Author
ORCID:
0000-0001-9827-9836
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author
ORCID:
0000-0001-7774-7215
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Role:
Author
ORCID:
0000-0001-9934-9023

Contributors

Publisher:
Elsevier
Journal:
Lancet HIV More from this journal
Volume:
8
Issue:
8
Pages:
E474-E485
Publication date:
2021-06-18
Acceptance date:
2021-05-14
DOI:
ISSN:
2405-4704
Language:
English
Keywords:
Pubs id:
1182442
Local pid:
pubs:1182442
Deposit date:
2021-06-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP